Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              Boehringer Ingelheim GmbH

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry
              Flag Germany
              Virtual Booth Virtual Booth

              20th Annual Contact Pharma

              Participation Not Confirmed

              Update your events

              Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH a...

              Lead Product(s): BI 456906

              Therapeutic Area: Nutrition and Weight Loss Product Name: BI 456906

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Zealand Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 13, 2021

              Details:

              The Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate GLP-1/glucagon dual agonist, BI 456906, in people with obesity or who are overweight with a BMI 27 kg/m2 or higher without diabetes.

              PharmaCompass__DigitalAd